Comparison of cardioprotective efficacy of two thromboxane A2 receptor antagonists

被引:8
|
作者
Ge, ZD
Auchampach, JA
Piper, GM
Gross, GJ
机构
[1] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Div Transplant Surg, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA
关键词
hydroxyl radicals; ischemia; KT2-962-TXA(2) receptor antagonist; reperfusion;
D O I
10.1097/00005344-200303000-00018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of the current study was to compare the efficacy of two structurally unrelated thromboxane A(2) (TXA(2)) receptor antagonists, KT2-962 and daltroban (BM 13.505), in a dog model of myocardial ischemia/reperfusion injury. Pentobarbital-anesthetized dogs were subjected to left circumflex coronary artery occlusion for 90 minutes followed by 5 hours of reperfusion. Vehicle, KT2-962(10 mg/kg), or daltroban (10 mg/kg) were administered as intravenous boluses 10 minutes before coronary occlusion. Systemic hemodynamics were measured throughout the experiments and regional myocardial blood flow was measured by the radioactive microsphere technique. At the end of the reperfusion period; myocardial infarct size was quantified by staining with triphenyltetrazolium chloride. Neither KT2-962 nor daltroban significantly altered heart rate, mean arterial blood pressure, or regional myocardial blood flow. The content of myeloperoxidase activity in the ischemic/reperfused tissue, an index of neutrophil infiltration, was not significantly different among the three treatment groups. However, administration of KT2-962, but not daltroban, significantly reduced the incidence of ventricular fibrillation during the ischemic period and significantly reduced myocardial infarct size expressed as a percentage of the risk region (approximately 40%). Subsequent in-vitro assays using electron spin resonance spectroscopy demonstrated that KT2-962 inhibited the formation of hydroxyl radicals, whereas daltroban had no effect. These results suggest that the beneficial effects of KT2-962 may be due to its direct free radical scavenging properties rather than its ability to block TXA(2) receptors.
引用
收藏
页码:481 / 488
页数:8
相关论文
共 50 条
  • [11] Effect of serotonin and thromboxane A2 on endothelial cell proliferation:: Effect of specific receptor antagonists
    Pakala, R
    Benedict, CR
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 131 (06): : 527 - 537
  • [12] NONPROSTANOID THROMBOXANE A2 RECEPTOR ANTAGONISTS WITH A DIBENZOXEPIN RING-SYSTEM .1.
    OHSHIMA, E
    TAKAMI, H
    SATO, H
    OBASE, H
    MIKI, I
    ISHII, A
    KARASAWA, A
    KUBO, K
    JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (18) : 3394 - 3402
  • [13] Comparison of thromboxane A2 with thromboxane A3: Receptor binding properties and effects on platelet aggregation
    Delong, CJ
    Wada, M
    Smith, E
    Wilson, S
    Warnock, M
    Fitzgerald, GA
    Schmaier, A
    Smith, WL
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2006, 79 (1-2) : 173 - 173
  • [14] A Novel Antagonist for the Thromboxane A2 Receptor
    Khasawneh, Fadi T.
    Ting, Harold J.
    FASEB JOURNAL, 2010, 24
  • [15] Thromboxane receptor antagonists
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1998, 3 (12) : 562 - 562
  • [16] PHARMACOLOGY OF THROMBOXANE-A2 RECEPTOR ANTAGONISTS
    HALUSHKA, PV
    ZEITSCHRIFT FUR KARDIOLOGIE, 1989, 78 : 42 - 47
  • [17] Development of dual-acting benzofurans and benzomorpholines as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists
    Ohno, Michihiro
    Takeda, Takahiro
    Tanaka, Yoichiro
    Makita, Kei
    Miyamoto, Mitsuko
    Yamada, Naohiro
    Ohtake, Atsushi
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2560 - U2560
  • [18] Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors
    Rolin, S
    Dogne, JM
    Vastersaegher, C
    Hanson, J
    Masereel, B
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2004, 74 (1-4) : 75 - 86
  • [20] PHARMACOKINETICS AND PHARMACODYNAMICS OF A THROMBOXANE A2 RECEPTOR ANTAGONIST
    FRIEDHOFF, LT
    FRY, J
    IVASHKIV, E
    JEMAL, M
    WILLARD, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (02) : 139 - 139